Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
This article was originally published in PharmAsia News
Executive Summary
U.S. biotech firm Alexion Pharmaceuticals, which submitted a NDA in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder, could benefit from the country's practice of placing a premium on innovative drugs for orphan diseases